

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM783524

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	Release of Security Interest Recorded at Reel/Frame 7283/0600		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Fortress Credit Corp., as Agent		01/31/2023	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	THERAGEN, INC.		
Street Address:	11220 ASSETT LOOP, SUITE 101		
City:	MANASSAS		
State/Country:	VIRGINIA		
Postal Code:	20109		
Entity Type:	Corporation: DELAWARE		
PROPERTY NUMBERS Total: 5			
Property Type	Number	Word Mark	
Registration Number:	3720117	KNEEHAB	
Registration Number:	2639442	NEUROTECH	
Serial Number:	88369269	ACTASTIM	
Serial Number:	88369252	THERAGEN	
Serial Number:	88369266	THERAGEN	
CORRESPONDENCE DATA			
Fax Number:	2149813400		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	214-981-3483		
Email:	dclark@sidley.com		
Correspondent Name:	Dusan Clark, Esq.		
Address Line 1:	Sidley Austin LLP		
Address Line 2:	2021 McKinney Ave., Suite 2000		
Address Line 4:	Dallas, TEXAS 75201		
ATTORNEY DOCKET NUMBER:	015171-30830		
NAME OF SUBMITTER:	Dusan Clark		
SIGNATURE:	/Dusan Clark/		
DATE SIGNED:	01/31/2023		

CH \$140.00 3720117

Total Attachments: 5

source=34. Theragen - IPSA Release by Fortress Credit Corp (Executed)#page1.tif

source=34. Theragen - IPSA Release by Fortress Credit Corp (Executed)#page2.tif

source=34. Theragen - IPSA Release by Fortress Credit Corp (Executed)#page3.tif

source=34. Theragen - IPSA Release by Fortress Credit Corp (Executed)#page4.tif

source=34. Theragen - IPSA Release by Fortress Credit Corp (Executed)#page5.tif

**RELEASE OF SECURITY INTEREST
IN INTELLECTUAL PROPERTY COLLATERAL**

THIS RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY COLLATERAL (this “Release”), dated as of January 31, 2023, is made by Fortress Credit Corp., in its capacity as administrative and collateral agent (the “Agent”), in favor of THERAGEN, INC., a Delaware corporation (“Grantor”), as follows:

WITNESSETH:

WHEREAS, pursuant to that certain Credit Agreement, dated as of May 6, 2021 (as amended, amended and restated, restated, supplemented or otherwise modified, extended, replaced, or refinanced from time to time, the “Credit Agreement”), by the Grantor in favor of the Agent, and those certain agreements described on Annex I attached hereto (the “IP Security Agreements”), the Grantor granted a security interest in certain collateral in favor of the Agent, including the IP Collateral (as hereinafter defined); and

WHEREAS, the Agent now desires to terminate and release the IP Security Agreements and the entirety of its security interest in the IP Collateral described on Annex II attached hereto.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and upon the terms set forth in this Release, the Agent hereby agrees as follows:

1. Definitions. The term “IP Collateral”, as used herein, shall mean all of the Grantors’ right, title or interest in, or to any and all of the Trademark Collateral and Patent Collateral, including the properties listed on Annex II attached hereto. Capitalized terms not defined herein have the meanings set forth in the Credit Agreement, or IP Security Agreements, as applicable.

2. Release of Security Interest. The Agent, without recourse, representation or warranty and at the Grantors’ sole cost and expense, hereby terminates, cancels, releases, relinquishes and discharges, in its entirety, for the benefit of the Grantors, and their successors and assigns, its security interest in and to the IP Collateral, the IP Security Agreements and any and all right, title and interest of the Agent in and to the IP Collateral and under the IP Security Agreements shall hereby be terminated, cancelled, released, relinquished and discharged. The Agent hereby authorizes the Grantors and their successors, assigns or other legal representatives to file this Release with the United States Patent and Trademark Office, at the sole expense of the Grantors, to evidence and effectuate the release and termination of the Agent’s security interest in the IP Collateral.


3. Delivery by Facsimile. Delivery of an executed signature page to this Release by facsimile or electronic (including .pdf file) transmission shall be as effective as delivery of a manually signed counterpart of this Release. Electronic signatures will have the same force and effect as manual signatures.

4. Governing Law. THIS RELEASE AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HERETO SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK.

[Signature page follows]

IN WITNESS WHEREOF, the undersigned has executed this Release by its duly authorized officer as of the date first above written.

FORTRESS CREDIT CORP., as Agent

By: 
Name: Avraham Dreyfuss
Title: Chief Financial Officer

ANNEX I

Trademark Security Agreement by Theragen, Inc., a Delaware corporation, in favor of Fortress Credit Corp., as administrative and collateral agent, dated as of May 6, 2021 and recorded with the United States Patent and Trademark Office on May 6, 2021 at Reel 7283, Frame 0600.

Patent Security Agreement by Theragen, Inc., a Delaware corporation, in favor of Fortress Credit Corp., as administrative and collateral agent, dated as of May 6, 2021 and recorded with the United States Patent and Trademark Office on May 6, 2021 at Reel 56162, Frame 0569.

ANNEX II

Trademark Registrations

Reel 7283, Frame 0600

Registered Trademarks

Mark	Registration No.	Serial No.	Country	Filing Date	Owner
NT MEDITENS PLUS	002409878	002409878	Europe	10/12/2001	Bio-Medical Research Limited
NT MEDITENS PLUS	UK00902409878	UK00902409878	UK (Clone)	10/12/2001	Bio-Medical Research Limited
KNEEHAB	3,720,117	78/727,873	United States	10/06/2005	Theragen, Inc.
NEUROTECH	2,639,442	76/363,895	United States	1/25/2002	Theragen, Inc.

Pending Trademark Applications

Mark	Serial No.	Country	Filing Date	Publication Date	Owner
ACTASTIM	88/369,269	United States	4/03/2019	7/23/2019	Theragen, Inc.
THERAGEN	88/369,252	United States	4/03/2019	7/23/2019	Theragen, Inc.
THERAGEN and Design	88/369,266	United States	4/03/2019	7/23/2019	Theragen, Inc.

Patent Registrations

Reel 56162 , Frame 569

Patent Registrations and Applications:

a. Issued Patents

Patent No.	Appl. No.	Country	Filing Date	Title	Owner
EP 1620169	04743752.0	Europe	5/07/2004	Apparatus for Applying Electrical Current to the Neuromuscular System	Theragen LLC
JP 5192690	2006-506629	Japan	5/07/2004	Apparatus for Applying Electrical Current to the Neuromuscular System	BMR Research & Development LTD
JP 5465191	2011-005533	Japan	1/14/2011	Apparatus for Applying Electrical Current to the Neuromuscular System	BMR Research & Development LTD
US 7,957,816	10/555,732	United States	5/07/2004	Apparatus for Applying Electrical Current to the Neuromuscular System	Theragen, Inc.
US 8,209,030	13/102,668	United States	5/06/2011	Apparatus for Applying Electrical Current to the Neuromuscular System	Theragen, Inc.
CZ 1620169	2004743752	Czech Republic	5/07/2004	Apparatus for Applying Electrical Current to the Neuromuscular System	Theragen LLC

b. Pending Applications

Publ. No.	Appl. No.	Country	Filing Date	Title	Owner
n/a	63/146,196	United States	2/05/2021	Therapeutic Stimulator System	N/A